Navigation Links
Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference

KING OF PRUSSIA, Pa., April 22, 2013 /PRNewswire/ -- Trevena, Inc. a clinical stage pharmaceutical company today announced that its President and CEO, Dr. Maxine Gowen will present at the 12th Annual Needham Healthcare Conference on May 1, 2013, 10:00am, at Grand Hyatt New York.  

Dr. Gowen will provide a detailed overview of the company's most advanced clinical programs which include TRV027, a biased ligand for the treatment of acute heart failure, which is currently in Phase 2 studies, and TRV130, in Phase 1b studies for acute pain where intravenous therapy is needed. First-in-man study results on the safety, tolerability, and pharmacology of TRV130 in healthy volunteers were recently presented at the American Academy of Neurology.

The complete slide presentation of Dr Gowen's presentation will be available on Trevena's website ( under the About Trevena tab.

Dr. Gowen will be available for one-on-one meetings with the investment community during the conference. Please contact conference organizers to secure a meeting time.

About Trevena and Biased Ligands

Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines. GPCRs are the targets for at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR, to unlock new biology and avoid drug adverse effects.  The discovery platform is applicable to a wide range of druggable targets and diseases.  Trevena is based in King of Prussia, Pennsylvania and is backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company.

CONTACT: Kimberly Minarovich , 917-533-3268,

SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmagen to Present Strategic Vision for Solving Nations Parenteral Drug Shortage Crisis at 2013 BIO International Convention
2. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
3. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
4. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
5. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Cantel Medical To Present At Needham 12th Annual Healthcare Conference
8. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
9. Soligenix to Present at World Vaccine Congress & Expo
10. 20+ SynCardia Certified Centers to Present Record Number of Total Artificial Heart Abstracts at ISHLT
11. Novocure Presents Preclinical Data at the American Association for Cancer Research (AACR)
Post Your Comments:
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of California Berkeley, and other leading institutions in announcing the launch of the ... to change the way animals are raised for food. , Founding members of ...
Breaking Medicine News(10 mins):